Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162748 | 0.97 | LMNA (0.44) | LMNAGAAL3MBTL1MAPTMEN1 | |
| SCHEMBL3883846 | 0.95 | POLB (0.43) | LMNAGAAL3MBTL1MAPTMEN1 | |
| SCHEMBL4167455 | 0.81 | PDE7A (0.49) | MAPTPGR | |
| SCHEMBL5516089 | 0.77 | MAPK1 (0.49) | LMNAGAAMAPTMEN1KMT2A | |
| Brofoxine SCHEMBL61925 | 0.76 | PGR (0.59) | PGR | |
| Brofoxine SCHEMBL29710912 | 0.76 | PGR (0.59) | PGR | |
| SCHEMBL4848524 | 0.73 | MAPK1 (0.49) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL5499005 | 0.72 | PGR (0.55) | LMNAMAPTPOLBCYP3A4CYP2C19 | |
| SCHEMBL31693946 | 0.72 | LMNA (0.44) | LMNAGAAL3MBTL1MAPTMEN1 | |
| SCHEMBL5514742 | 0.72 | MAPT (0.41) | LMNAGAAL3MBTL1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268149-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-7192956-B2 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1531824-A4 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1515725-A4 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1531824-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | Wyeth (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1515725-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH | 2004-01-22 | — | — | US | disclosed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000230-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | LMNA 844/4885GAA 4856/4885L3MBTL1 3693/4885 |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | NR5A1, MC1R, CYP17A1 | LMNA 4684/4885GAA 4867/4885L3MBTL1 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.